A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country
<h3>Background</h3><p dir="ltr">Sodium glucose co-transporter 2 inhibitors (SGLT2is) are a novel class of oral antidiabetic drugs. To date, there are no pharmacoepidemiologic studies investigating the pattern of use of SGLT2is compared to other oral antidiabetic drugs in...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513568147243008 |
|---|---|
| author | Nancy Zaghloul (14147865) |
| author2 | Ahmed Awaisu (5121473) Ahmed Mahfouz (737928) Sumaya Alyafei (14147868) Hazem Elewa (3592601) |
| author2_role | author author author author |
| author_facet | Nancy Zaghloul (14147865) Ahmed Awaisu (5121473) Ahmed Mahfouz (737928) Sumaya Alyafei (14147868) Hazem Elewa (3592601) |
| author_role | author |
| dc.creator.none.fl_str_mv | Nancy Zaghloul (14147865) Ahmed Awaisu (5121473) Ahmed Mahfouz (737928) Sumaya Alyafei (14147868) Hazem Elewa (3592601) |
| dc.date.none.fl_str_mv | 2022-09-28T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1007/s11096-022-01464-x |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/A_5-year_trend_in_the_use_of_sodium-glucose_co-transporter_2_inhibitors_and_other_oral_antidiabetic_drugs_in_a_Middle_Eastern_country/21592404 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Health sciences Public health Diabetes mellitus Hypoglycemic agents Qatar Sodium-glucose transporter 2 inhibitors Trends Type 2 |
| dc.title.none.fl_str_mv | A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr">Sodium glucose co-transporter 2 inhibitors (SGLT2is) are a novel class of oral antidiabetic drugs. To date, there are no pharmacoepidemiologic studies investigating the pattern of use of SGLT2is compared to other oral antidiabetic drugs in the Middle East, including Qatar.</p><h3>Aim</h3><p dir="ltr">This study aimed to explore the trends in the use of SGLT2is compared to other oral antidiabetic drugs in Qatar from 2016 to 2020.</p><h3>Method</h3><p dir="ltr">This is a descriptive, retrospective cross-sectional study where information on all oral antidiabetic drugs dispensed as in- or out-patient prescriptions from 2016 to 2020 in Hamad Medical Corporation hospitals, Qatar were collected. Outcomes included the number and relative frequency of quarterly prescriptions of different oral antidiabetic drug classes [biguanides, sulfonylureas, dipeptidyl peptidase 4 inhibitors, thiazolidinediones, meglitinides, α-glucosidase inhibitors, and SGLT2is] prescribed from 2016 to 2020.</p><h3>Results</h3><p dir="ltr">SGLT2is prescriptions increased from 1045 (2.13%) in 2017 to 8375 (12.39%) in 2020, while sulfonylureas prescriptions declined from 10,436 (21.25%) to 9158 (13.55%) during the same period. Metformin use decreased from 23,926 (48.71%) in 2017 to 30,886 (45.70%) in 2020. The proportions of thiazolidinediones, meglitinides, α-glucosidase inhibitors prescriptions remained stable over the years. Among SGLT2is, empagliflozin prescriptions showed an increase from 537 (10.65%) to 2881 (34.40%) compared to dapagliflozin, which decreased by the end of 2018 from 4505 (89.35%) to 5494 (65.6%).</p><h3>Conclusion</h3><p dir="ltr">SGLT2is have largely replaced sulfonylureas in Qatar. The increasing trend in their use over the years is similar to that reported in other countries. The trend among SGLT2is suggests greater preference for empagliflozin over dapagliflozin.</p><h2>Other Information</h2><p dir="ltr">Published in: International Journal of Clinical Pharmacy<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s11096-022-01464-x" target="_blank">http://dx.doi.org/10.1007/s11096-022-01464-x</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_ab785aa637b3b14b28c0e374fe4719be |
| identifier_str_mv | 10.1007/s11096-022-01464-x |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21592404 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern countryNancy Zaghloul (14147865)Ahmed Awaisu (5121473)Ahmed Mahfouz (737928)Sumaya Alyafei (14147868)Hazem Elewa (3592601)Biomedical and clinical sciencesClinical sciencesPharmacology and pharmaceutical sciencesHealth sciencesPublic healthDiabetes mellitusHypoglycemic agentsQatarSodium-glucose transporter 2 inhibitorsTrendsType 2<h3>Background</h3><p dir="ltr">Sodium glucose co-transporter 2 inhibitors (SGLT2is) are a novel class of oral antidiabetic drugs. To date, there are no pharmacoepidemiologic studies investigating the pattern of use of SGLT2is compared to other oral antidiabetic drugs in the Middle East, including Qatar.</p><h3>Aim</h3><p dir="ltr">This study aimed to explore the trends in the use of SGLT2is compared to other oral antidiabetic drugs in Qatar from 2016 to 2020.</p><h3>Method</h3><p dir="ltr">This is a descriptive, retrospective cross-sectional study where information on all oral antidiabetic drugs dispensed as in- or out-patient prescriptions from 2016 to 2020 in Hamad Medical Corporation hospitals, Qatar were collected. Outcomes included the number and relative frequency of quarterly prescriptions of different oral antidiabetic drug classes [biguanides, sulfonylureas, dipeptidyl peptidase 4 inhibitors, thiazolidinediones, meglitinides, α-glucosidase inhibitors, and SGLT2is] prescribed from 2016 to 2020.</p><h3>Results</h3><p dir="ltr">SGLT2is prescriptions increased from 1045 (2.13%) in 2017 to 8375 (12.39%) in 2020, while sulfonylureas prescriptions declined from 10,436 (21.25%) to 9158 (13.55%) during the same period. Metformin use decreased from 23,926 (48.71%) in 2017 to 30,886 (45.70%) in 2020. The proportions of thiazolidinediones, meglitinides, α-glucosidase inhibitors prescriptions remained stable over the years. Among SGLT2is, empagliflozin prescriptions showed an increase from 537 (10.65%) to 2881 (34.40%) compared to dapagliflozin, which decreased by the end of 2018 from 4505 (89.35%) to 5494 (65.6%).</p><h3>Conclusion</h3><p dir="ltr">SGLT2is have largely replaced sulfonylureas in Qatar. The increasing trend in their use over the years is similar to that reported in other countries. The trend among SGLT2is suggests greater preference for empagliflozin over dapagliflozin.</p><h2>Other Information</h2><p dir="ltr">Published in: International Journal of Clinical Pharmacy<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s11096-022-01464-x" target="_blank">http://dx.doi.org/10.1007/s11096-022-01464-x</a></p>2022-09-28T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s11096-022-01464-xhttps://figshare.com/articles/journal_contribution/A_5-year_trend_in_the_use_of_sodium-glucose_co-transporter_2_inhibitors_and_other_oral_antidiabetic_drugs_in_a_Middle_Eastern_country/21592404CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215924042022-09-28T06:00:00Z |
| spellingShingle | A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country Nancy Zaghloul (14147865) Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Health sciences Public health Diabetes mellitus Hypoglycemic agents Qatar Sodium-glucose transporter 2 inhibitors Trends Type 2 |
| status_str | publishedVersion |
| title | A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country |
| title_full | A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country |
| title_fullStr | A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country |
| title_full_unstemmed | A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country |
| title_short | A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country |
| title_sort | A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country |
| topic | Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Health sciences Public health Diabetes mellitus Hypoglycemic agents Qatar Sodium-glucose transporter 2 inhibitors Trends Type 2 |